CY1126361T1 - Πολυμερη νουκλεϊνικων οξεων με χηλικη φωσφοροδιαταξη για χρηση σε συνδυασμο με αναστολεα πολυμερασης hbv για τη θεραπεια λοιμωξεων απο τον ιο της ηπατιτιδας β και της ηπατιτιδας δ - Google Patents

Πολυμερη νουκλεϊνικων οξεων με χηλικη φωσφοροδιαταξη για χρηση σε συνδυασμο με αναστολεα πολυμερασης hbv για τη θεραπεια λοιμωξεων απο τον ιο της ηπατιτιδας β και της ηπατιτιδας δ

Info

Publication number
CY1126361T1
CY1126361T1 CY20231100626T CY231100626T CY1126361T1 CY 1126361 T1 CY1126361 T1 CY 1126361T1 CY 20231100626 T CY20231100626 T CY 20231100626T CY 231100626 T CY231100626 T CY 231100626T CY 1126361 T1 CY1126361 T1 CY 1126361T1
Authority
CY
Cyprus
Prior art keywords
hepatitis
treatment
chelized
phosphore
combination
Prior art date
Application number
CY20231100626T
Other languages
Greek (el)
English (en)
Inventor
Andrew Vaillant
Original Assignee
Replicor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1126361(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc. filed Critical Replicor Inc.
Publication of CY1126361T1 publication Critical patent/CY1126361T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CY20231100626T 2014-07-10 2023-11-07 Πολυμερη νουκλεϊνικων οξεων με χηλικη φωσφοροδιαταξη για χρηση σε συνδυασμο με αναστολεα πολυμερασης hbv για τη θεραπεια λοιμωξεων απο τον ιο της ηπατιτιδας β και της ηπατιτιδας δ CY1126361T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US201462091943P 2014-12-15 2014-12-15

Publications (1)

Publication Number Publication Date
CY1126361T1 true CY1126361T1 (el) 2026-02-25

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20231100626T CY1126361T1 (el) 2014-07-10 2023-11-07 Πολυμερη νουκλεϊνικων οξεων με χηλικη φωσφοροδιαταξη για χρηση σε συνδυασμο με αναστολεα πολυμερασης hbv για τη θεραπεια λοιμωξεων απο τον ιο της ηπατιτιδας β και της ηπατιτιδας δ

Country Status (34)

Country Link
US (1) US9603865B2 (enExample)
EP (1) EP3166615B1 (enExample)
JP (2) JP2017521433A (enExample)
KR (2) KR102734495B1 (enExample)
CN (2) CN106659730A (enExample)
AU (1) AU2015286199B2 (enExample)
BR (1) BR112017000320B1 (enExample)
CA (1) CA2954182C (enExample)
CL (1) CL2017000008A1 (enExample)
CU (1) CU20170001A7 (enExample)
CY (1) CY1126361T1 (enExample)
DK (1) DK3166615T3 (enExample)
DO (1) DOP2017000002A (enExample)
EA (1) EA036745B1 (enExample)
EC (1) ECSP16097355A (enExample)
ES (1) ES2963814T3 (enExample)
FI (1) FI3166615T3 (enExample)
HK (1) HK1231402A1 (enExample)
HR (1) HRP20231400T1 (enExample)
HU (1) HUE064449T2 (enExample)
IL (1) IL249660B (enExample)
LT (1) LT3166615T (enExample)
MD (1) MD4760C8 (enExample)
MX (1) MX381042B (enExample)
MY (1) MY178087A (enExample)
PH (1) PH12017500010B1 (enExample)
PL (1) PL3166615T3 (enExample)
PT (1) PT3166615T (enExample)
RS (1) RS64833B1 (enExample)
SG (1) SG11201700073PA (enExample)
SI (1) SI3166615T1 (enExample)
SM (1) SMT202300380T1 (enExample)
TW (1) TWI766831B (enExample)
WO (1) WO2016004525A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005357A (es) * 2018-11-08 2021-06-30 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos.
US11166976B2 (en) * 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN112010905B (zh) * 2020-05-07 2021-09-03 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦晶型及其应用
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
CA3200094A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
JP2005538186A (ja) 2002-09-13 2005-12-15 レプリコール インコーポレーティッド 非配列相補性の抗ウイルス性オリゴヌクレオチド
US9474793B2 (en) * 2005-02-22 2016-10-25 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus
KR20150039873A (ko) 2010-08-20 2015-04-13 레플리코르 인코포레이티드 올리고뉴클레오타이드 킬레이트 복합체
EP3766975A1 (en) * 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
CA2873529C (en) 2012-05-18 2020-08-18 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
EP2890403A4 (en) * 2012-08-30 2016-03-09 Replicor Inc METHOD FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS

Also Published As

Publication number Publication date
JP6922030B2 (ja) 2021-08-18
DK3166615T3 (da) 2023-11-13
MX381042B (es) 2025-03-12
KR102734495B1 (ko) 2024-11-25
CL2017000008A1 (es) 2017-06-09
TW201613617A (en) 2016-04-16
CA2954182A1 (en) 2016-01-14
US20160008393A1 (en) 2016-01-14
SG11201700073PA (en) 2017-02-27
MD4760B1 (ro) 2021-07-31
EA036745B1 (ru) 2020-12-16
KR20170029577A (ko) 2017-03-15
BR112017000320A2 (pt) 2017-11-07
FI3166615T3 (fi) 2023-11-06
DOP2017000002A (es) 2017-03-15
HK1231402A1 (zh) 2017-12-22
TWI766831B (zh) 2022-06-11
PT3166615T (pt) 2023-11-13
AU2015286199B2 (en) 2020-05-14
JP2020143065A (ja) 2020-09-10
SI3166615T1 (sl) 2023-12-29
EP3166615A4 (en) 2018-01-17
EP3166615A1 (en) 2017-05-17
EA201790160A1 (ru) 2017-06-30
AU2015286199A1 (en) 2017-02-23
US9603865B2 (en) 2017-03-28
HRP20231400T1 (hr) 2024-02-16
PL3166615T3 (pl) 2024-02-19
CA2954182C (en) 2023-08-15
BR112017000320B1 (pt) 2023-02-07
PH12017500010A1 (en) 2017-05-15
ECSP16097355A (es) 2017-03-31
SMT202300380T1 (it) 2024-01-10
NZ727583A (en) 2024-08-30
PH12017500010B1 (en) 2022-07-29
MD20170014A2 (ro) 2017-07-31
MY178087A (en) 2020-10-02
KR20230070330A (ko) 2023-05-22
HUE064449T2 (hu) 2024-03-28
EP3166615B1 (en) 2023-08-09
CN113750112A (zh) 2021-12-07
RS64833B1 (sr) 2023-12-29
JP2017521433A (ja) 2017-08-03
CU20170001A7 (es) 2017-04-05
IL249660B (en) 2022-02-01
ES2963814T3 (es) 2024-04-02
MD4760C8 (ro) 2022-02-28
WO2016004525A1 (en) 2016-01-14
LT3166615T (lt) 2024-01-25
CN106659730A (zh) 2017-05-10
IL249660A0 (en) 2017-02-28
MX2017000053A (es) 2017-05-01

Similar Documents

Publication Publication Date Title
PH12017500010A1 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
CY1124327T1 (el) Τροποποιηση της εκφρασης του ιου ηπατιτιδας β (hbv)
CY1122520T1 (el) Συνθεσεις irna ιου ηπατιτιδας β (hbv) και μεθοδοι χρησης εξ αυτων
HK1248278A1 (zh) 用於使乙型肝炎病毒基因表达沉默的组合物及方法
DK3512863T3 (da) 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
EP3494123A4 (en) ARNI AGENT AGAINST HEPATITIS B INFECTION
WO2016183366A3 (en) Compositions and methods for silencing expression of hepatitis d virus rna
MX373703B (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
CY1123849T1 (el) Θεραπεια της λοιμωξης του ιου της ηπατιτιδας δελτα
CR20170174A (es) Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
CY1116374T1 (el) Θεραπεια για τη λοιμωξη με τον ιο της ηπατιτιδας β μονο ή σε συνδυασμο με τον ιο της ηπατιτιδας δελτα και σχετιζομενες ασθενειες του ηπατος
CY1124220T1 (el) Θεραπεια της λοιμωξης του ιου της ηπατιτιδας δελτα με ιντερφερονη λαμδα
MX2018003290A (es) Medios para el tratamiento del vih.
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
MA40218A (fr) Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d
NZ727583B2 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
TH1601005264A (enExample)
CL2015000978A1 (es) Compuestos peptidicos condensados con heterociclos o sus sales, como inhibidores del virus de la hepatitis c; composicion que los comprende; y su uso para el tratamiento de infeccion por vhc en un paciente.
MX391771B (es) Oligonucleótidos y proceso para detectar el virus de la influenza a h1n1.
RU2014143385A (ru) Способы воздействия на экспрессию гена TP53